drug
tigecycline
Marketedupdated 3mo agoby Meitheal Pharmaceuticals Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying tigecycline
- phase2Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
- —Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 24, 2028
~2.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Apr 7, 2033formulationUS 9855335
- Oct 8, 2030formulationUS 83729954.1y
- Feb 5, 2029formulationUS 78798282.5y
- Oct 24, 2028formulationUS 89752422.2y
- Mar 13, 2026formulationUS 10588975
- Mar 13, 2026formulationUS 9254328
- Mar 13, 2026formulationUS 9694078
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that